Heterobifunctional Molecule Screening for E3 Ligase Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively target and inhibit membrane-bound receptors involved in disease progression, such as cancer, autoimmune diseases, and inflammatory disorders, due to challenges in reaching sufficient plasma concentrations without toxicity and the risk of compensatory receptor stabilization or upregulation leading to therapy resistance.
Innovation Solution
A method for identifying and utilizing heterobifunctional molecules that simultaneously bind to transmembrane E3 ubiquitin ligases and membrane-bound proteins, inducing ubiquitination and internalization of these proteins, thereby reducing their surface levels and promoting degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If neutralizing antibodies or small molecule inhibitors are used to block receptor activity, then receptor activity is inhibited, but sufficient plasma concentrations cannot be achieved without inducing toxicity
Solution Approach 1:
The patent uses endogenous E3 ubiquitin ligases as intermediary molecules to mediate receptor degradation. Instead of directly inhibiting receptors with antibodies or small molecules (which cause toxicity at effective concentrations), the invention employs heterobifunctional molecules that recruit cellular ubiquitin ligases to ubiquitinate and degrade the target receptor through the proteasomal or lysosomal pathways. This intermediary mechanism allows for potent receptor inhibition via degradation rather than direct binding, achieving therapeutic effects at lower concentrations with reduced off-target toxicity.
Solution Approach 2:
The patent changes the mechanism of receptor inactivation from reversible non-covalent binding (antibodies/small molecules) to irreversible covalent modification through ubiquitination. By altering the biochemical parameter of receptor inactivation from transient blocking to permanent degradation, the system achieves sustained therapeutic effect with lower drug concentrations, thereby reducing plasma concentration-related toxicity.
2Reliability
If neutralizing antibodies are used to block receptor activity, then receptor signaling is inhibited, but compensatory receptor stabilization or upregulation occurs leading to therapy resistance
Solution Approach 1:
The patent employs E3 ubiquitin ligases as intermediary enzymes that directly modify the target receptor through ubiquitination, marking it for degradation. This intermediary enzymatic action bypasses the compensatory stabilization mechanisms that occur with direct antibody binding, as the receptor is actively targeted for destruction rather than passively blocked, preventing upregulation and resistance development.
Solution Approach 2:
The patent fundamentally changes the stability parameter of the target receptor by inducing active degradation through ubiquitination rather than reversible binding. This parameter change from stable blocking to active degradation ensures sustained receptor downregulation without compensatory upregulation, preventing therapy resistance.
3Reliability
If heterobifunctional molecules are used to induce ubiquitination and internalization, then protein surface levels decrease significantly, but the complexity of molecule design and screening increases
Solution Approach 1:
The patent segments the heterobifunctional molecule into two distinct functional domains: a target-specific binding domain (antibody or antibody fragment) and a ubiquitin ligase binding domain. This segmentation allows independent optimization of each domain and simplifies the screening process, as libraries can be constructed by combing pre-characterized binding domains with validated E3 ligase targets, reducing overall design complexity while maintaining potent protein level reduction.
Solution Approach 2:
The patent employs universal E3 ubiquitin ligase binding domains that can recognize multiple transmembrane E3 ligases, creating multi-functional heterobifunctional molecules. This universality reduces design complexity by allowing a single ligase-binding domain to work with multiple target receptors, simplifying the screening process and enabling broad applicability across different disease targets.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for potent and specific targeting of membrane-bound proteins with reduced off-target toxicity, achieving significant decreases in protein surface levels and potentially inhibiting disease progression with prolonged pharmacodynamic effects.
Implementation Method 1
The transmembrane E3 ubiquitin ligase is capable of decreasing the surface level of the membrane-bound protein upon simultaneous binding to a heterobifunctional molecule, preferably by ubiquitination of the membrane-bound protein
Implementation Method 2
Posttranslational modification of the cytosolic regions of membrane-bound receptors with ubiquitin drives their rapid removal from the cell surface via induced endocytosis
Implementation Method 3
The internalised receptors may subsequently be subjected to lysosomal degradation
Data Source
AI summary
The invention pertains to a method to identify an effective combination of a transmembrane E3 ubiquitin ligase and a membrane-bound protein, wherein the combination is effective when the transmembrane E3 ubiquitin ligase is capable of decreasing the surface level of the membrane-bound protein upon forced dimerization, preferably by ubiquitination of the membrane-bound protein. The method of the invention comprises a step of exposing a cell to a heterobifunctional molecule, wherein the heterobifunctional molecule comprises a first binding domain capable of specific binding to an extracellular portion of the transmembrane E3 ubiquitin ligase, and a second binding domain capable of specific binding to an extracellular portion of the membrane-bound protein. The method further comprises a step of determining the decrease in surface level of the membrane-bound protein. The invention additionally pertains to a heterobifunctional molecule targeting an effective combination of a transmembrane E3 ubiquitin ligase and a membrane-bound protein.